104 results about "Somatotropic hormone" patented technology

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.

The invention provides a preparation method of yak bone collagen peptide, a composition for promoting skeletal development and application of the composition, and relates to the technical field of health food. The preparation method comprises the following steps: carrying out ultrasonic pretreatment on yak bones, and degreasing through supercritical CO2 to obtain a degreased product; mixing the degreased product with a fishy smell removing agent to obtain a fishy smell removing product; the fishy smell removing agent is an aqueous solution of a plant extract; the plant extract is selected from at least one of amomum tsao-ko extract, turmeric extract, green tea extract or momordica grosvenori extract; the fishy smell removal product is subjected to an enzymatic hydrolysis reaction through an immobilized compound enzyme reactor, wherein the compound enzyme is prolyl endopeptidase, papain and ficin; obtaining a crude product; carrying out ultrafiltration by adopting a filter membrane with the molecular weight cut-off of 1kDa, and adsorbing through macroporous resin. The yak bone collagen peptide and the composition prepared by the invention can obviously improve the body length, promote the skeletal development and promote the secretion of growth hormone, and meet the growth requirements of children.

The invention relates to the technical field of medicine, in particular to an early evaluation method for endocrine remission of pituitary growth hormone adenoma based on low Knosp grading, which comprises the following steps: acquiring preoperative and postoperative image data and preoperative and postoperative clinical data of a patient with low Knosp grading pituitary growth hormone adenoma; extracting imaging features used for early evaluation of postoperative endocrine remission from the preoperative and postoperative image data; extracting clinical features for early evaluation of postoperative endocrine remission from the preoperative and postoperative clinical data; and performing statistical analysis on the iconography characteristics and the clinical characteristics to obtain an early evaluation result of postoperative endocrine remission. According to the method, risk factors related to whether low-Knosp graded pituitary growth hormone adenoma postoperative endocrine remission can be relieved or not are screened out, then a prediction model is established through a statistical method, and then early prediction of low-Knosp graded pituitary growth hormone adenoma postoperative endocrine remission is achieved.

The application discloses application of SbWOX gene and SbBBM gene in corn breeding and a corn genetic transformation method, and relates to a bioengineering technology.The application provides a nucleic acid molecule with co-expression of SbWOX protein gene and SbBBM protein gene, and corresponding gene co-expression vectors and microbial transformants.The application also provides application of the co-expression of the SbWOX gene and the SbBBM gene in the corn genetic transformation method.The application obtains corresponding genes and mutant proteins based on the SbWOX gene and the SbBBM gene of sorghum, the two genes are co-expressed in the corn genetic transformation process, even without adding plant growth hormones in the antibiotic screening medium in the tissue culture process, the plant genetic transformation process can be normally completed, and the transformation efficiency and the regeneration efficiency of the corn can be remarkably improved, the transformation rate reaches 10.42%, and the differentiation rate reaches 32.89%.

The present invention describes for the first time a method for preventing and / or reversing the phenomenon of premature senescence of skin cells and complex chronic wounds, characterized in that an effective amount of the growth hormone secretagogue peptide GHRP6 is applied. Also object of the present invention is a method for treating cases of complex chronic wounds that have developed primary or secondary refractoriness caused by the development of a cellular senescence process, transforming them from refractory wounds to responsive wounds in the presence of proliferative agents with which they unexpectedly manage to reverse and restart the healing process. Complex chronic wounds include cases of diabetic foot ulcers, venous ulcers, pressure ulcers, radiation ulcers, and other types of chronic wounds that are characterized by refractoriness to all types of treatment. These cases currently have no effective treatments.

The invention relates to the technical field of biological medicine, in particular to polypeptide for promoting release of growth hormone and application of the polypeptide, the polypeptide is shown as a formula (I), and in addition, the invention further provides application of the polypeptide shown as the formula (I) in preparation of medicine for diagnosing and / or treating diseases related to human growth hormone deficiency. Formula (I)

The present invention provides processes for producing a bioengineered lung (BEL) from an acellular lung matrix that has been treated with growth hormones, seeded with primary lung cells, and cultured in a bioreactor. Also provided are BELs and methods of transplanting the BEL into a subject in need of a lung transplant, and methods for using BELs for the study of the lung microbiome and its role in lung development and remodeling.

Disclosed are a compound shown in formula I and racemate, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same, a preparation method thereof, and a use thereof as a GHSR agonist in the preparation of a drug for the diagnosis, prevention and / or treatment of growth hormone-dependent diseases, the structure of formula I is as follows:

A method for producing a metabolism-activated liver organ, comprising a step for culturing primary hepatocytes or hepatocyte-like cells in a differential medium to obtain a metabolism-activated liver organ, the differential medium is a medium containing a glucocorticoid receptor agonist and one or two selected from the group consisting of a growth hormone receptor agonist and a prolactin receptor agonist.

The invention discloses application of METTL14 in inhibition of pituitary tumor cell proliferation and prognosis evaluation, and relates to the technical field of medicines. Experiments prove that when METTL14 is knocked out, E-cadherin can be lowered, and N-cadherin and waveform protein can be increased, so that the migration ability and proliferation and invasion ability of GH3 cells are promoted, and the tumor forming ability and in-vivo hormone level of pituitary growth hormone tumors are improved. Therefore, the METTL14 can be used for preparing a product for diagnosing or treating pituitary growth hormone adenoma, which is beneficial to theoretically researching pituitary adenoma and developing a novel targeted drug, and provides a new direction for finding a tumor marker or a new treatment strategy related to novel pituitary growth hormone adenoma diagnosis and controlling pituitary growth hormone adenoma.

The invention belongs to the technical field of experimental animal nutriology and sterile animal culture, and particularly relates to a vitamin compound for prolonging the survival time of sterile zebra fish and a preparation method of the vitamin compound. The vitamin compound is prepared from the following components in parts by mass: 600 to 1000 parts of vitamin A, 4000 to 6000 parts of vitamin C, 10 to 30 parts of vitamin D3, 1500 to 2200 parts of vitamin E, 80 to 120 parts of vitamin K3, 15000 to 25000 parts of compound B vitamins and sterile culture water. The preparation method comprises the following steps: dissolving the vitamin raw materials in sterile culture water, performing ultrasonic assisted dissolution, and then filtering and sterilizing to obtain the vitamin supplement. When the vitamin supplement is used for feeding the sterile zebra fish, the survival time of the sterile zebra fish can be obviously prolonged, and the expression level of growth hormone genes and insulin-like growth factor genes can be up-regulated. The application value of the sterile zebrafish in scientific research is further expanded.

The invention relates to the technical field of poultry breeding, and particularly discloses an antibiotic-free breeding method for improving the quality of old yard black chickens based on compound plant alternate feeding, and in the growth process of chickens, plant complementary food and basic ration without antibiotics and growth promoting hormone are added for mixed feeding; the adding method of the plant complementary food comprises the following steps: (1) forming a three-day alternating unit according to the sequence of feeding fresh Chinese chives on the first day, feeding fresh wild wormwood on the second day and feeding fresh wild banana trees on the third day, and circularly repeating the mode until the chickens are slaughtered; (2) the adding proportion of the plant complementary food is increased along with the day age of the chickens, and the adding proportion is the mass percentage of the total feeding weight of the day. According to the antibiotic-free breeding method, the specific composite plant feed is adopted for alternate feeding, and the meat flavor, the nutritional value and the health level of the chickens are remarkably improved through functional complementation and time sequence collaboration of plant active ingredients.

The invention belongs to the technical field of biological medicines, and discloses a novel long-acting recombinant human growth hormone fusion protein. The fusion protein is obtained by fusion expression of human growth hormone (hGH) and an anti-human albumin nano antibody (VHH). And the long-acting principle is that the clearance rate is reduced by reversibly and widely combining with albumin with endogenous circulation. The fusion protein has the characteristics that 1, the fusion protein is obtained by fusion expression of two functional domains of hGH and VHH, hGH sequence mutation and complex chemical modification are not involved, the preparation method is simpler, and the sample uniformity is better; 2, in the fusion protein, the N end of the hGH protein has no additional structure, and the VHH functional domain is connected to the C end of the hGH, so that the influence on the activity of the hGH is reduced; and 3, animal efficacy results show that the fusion protein has a long-acting effect.

The application discloses a transdermal patch special for children with dwarfism, and relates to the technical field of medical treatment, which comprises a patch main body and a needle cylinder, and a fixed plate is fixedly connected to the inside of the patch main body, and the top and the bottom of the fixed plate are penetrated by the needle cylinder; the top of the needle cylinder is provided with a pressing plate, the bottom of the pressing plate is provided with a stand column on the two sides of the needle cylinder, the bottom of the two stand columns is arranged in the inside of the fixed plate and is slidably connected with the fixed plate; the two stand columns are both sleeved with a spring one; the top of the pressing plate is provided with a clamping groove, the bottom of the clamping groove is communicated with the needle cylinder, and a clamping seat is arranged in the clamping groove; the top of the pressing plate is provided with a fence; the two sides of the pressing plate are both provided with a connecting rod, one end of the connecting rod is connected with the pressing plate, and the other end penetrates through the top of the patch main body; the two sides of the patch main body close to the bottom are both provided with a sticking layer; and the two sides of the inside of the patch main body are both provided with a negative pressure sponge layer. The burden of the children with dwarfism is relieved, growth hormone injection treatment is facilitated, and the skin redness and swelling caused after growth hormone injection can be effectively prevented and treated.

The present invention relates to a customizable injectable solution comprising Human Growth Hormone (HGH), Insulin-like Growth Factor 1 (IGF-1), or a growth hormone secretagogue such as sermorelin or ipamorelin, combined with a blend of nutrients including amino acids, vitamins, electrolytes, functional mushroom extracts, and optionally mushroom mycelium. The solution is delivered via a dual-chamber syringe to preserve component stability, with mixing occurring immediately before administration. The formulation is suitable for subcutaneous, intramuscular, or intravenous injection and may be tailored for muscle growth, cognitive performance, immune support, or neuroregeneration. The invention also contemplates injectable formulations of functional mushrooms alone, as well as alternative delivery methods such as sublingual troches containing GH-inducing peptides, functional mushrooms, and ketamine. This system provides a versatile, bioavailable, and clinically adaptable approach to personalized health optimization.

The invention discloses a composition for promoting growth hormone secretion and nutrient absorption. The composition comprises gamma-aminobutyric acid, composite minerals, composite vitamins, lactobacillus fermentum and seasoning auxiliary materials. The preparation method comprises the following steps: (1) putting the weighed materials into a wet granulator, adding water according to the proportion, and granulating; (2) drying the granulated material, and controlling the moisture to be within 5%; and (3) adding seasoning auxiliary materials into the dried material particles, and mixing to obtain the composition. The composition provided by the invention provides enough nutrients while the gamma-aminobutyric acid promotes the secretion of growth hormones, so that the effects can be better exerted, and the aim of achieving a higher expected effect is achieved.

The invention relates to the technical field of medicines, in particular to application of a growth hormone releasing peptide Ghrelin receptor in itching intervention. By adjusting the activity of the receptor, the invention provides a new strategy for intervening pruritus: activation of the Ghrelin receptor can be used for inducing pruritus so as to construct a disease model; and inhibiting the Ghrelin receptor is used for preventing or treating pruritus, and the pruritus comprises acute pruritus and chronic pruritus. In specific implementation, the inhibition of the receptor is realized by applying the Ghrelin receptor antagonist, and the activation of the receptor is realized by applying the Ghrelin receptor agonist. Therefore, by targeting the Ghrelin receptor, controllable induction and efficient inhibition of pruritus are realized, mechanism innovation, treatment practicability and conversion feasibility are integrated, and a breakthrough strategy is provided for prevention and treatment of pruritus-related diseases.

The invention relates to a deep learning and logic correction segmentation combined bone age assessment method, which aims at the problems of high joint extraction false drop rate, difficulty in epiphysis maturity grade classification and the like, through a logic correction segmentation mechanism of confidence ranking, a semi-supervised pseudo-label generation strategy and a global attention enhancement module based on normalization, the bone age is assessed. And the accuracy and clinical robustness of bone age evaluation are remarkably improved. The application scenarios of the method include but are not limited to the precise medical fields of children endocrine dysplasia screening, bone age lag or advance pathological diagnosis, orthopedic treatment scheme making, growth hormone intervention curative effect evaluation and the like.

The application discloses a method for preparing GHR humanized animal cells by using a CRISPR system, which comprises the following steps: designing and synthesizing sgRNA; mixing the sgRNA with a Cas9 protein to form a CRISPR-Cas9 complex; constructing donor DNA containing coding sequences of a human GHR extracellular region and a rat GHR intracellular region; injecting the CRISPR-Cas9 complex and the donor DNA into the cytoplasm or nucleus of a rat fertilized ovum to knockout the coding sequence of the extracellular region of the rat-derived GHR gene and simultaneously insert the coding sequence of the extracellular region of the human-derived GHR gene into the genome, so that the GHR humanized animal cells are obtained. The application further discloses a method for constructing a GHR humanized rat model by using the CRISPR system, and application of the GHR humanized animal cells and the GHR humanized rat model obtained by the above method in drug screening, drug development or efficacy evaluation. The application can more accurately simulate the interaction between the human GHR and growth hormone and other ligands, improves the accuracy and reliability of research, and has the advantages of simple gene editing operation, high editing efficiency, strong specificity, low off-target effect and wide application range.

The invention discloses a sterile production method of a fresh dendrobium officinale protocorm product, which comprises the following steps: taking dendrobium officinale seeds from capsules of dendrobium officinale, repeatedly washing the capsules with tap water until the capsules are free of foam, sterilizing, cutting the capsules open, and drying to obtain the dendrobium officinale protocorm product. Uniformly spreading the seeds on an M2 solid culture medium, keeping the illumination condition of 500Lx and the temperature of 25 + / -1 DEG C, and waiting for the seedlings to grow for 60-90 days; wherein the M2 solid culture medium comprises 1 / 2 MS macroelements without exogenous hormones, 35% of banana juice, 35% of composite carbon source and 2% of agar powder. The method has the beneficial effects that a technical route map for mass production by infinitely stacking sterilization and ventilation culture of the small glass containers of 10 liters and getting rid of the constraint of a shaking table is provided. The technical key point is to screen out that the growth rate which can reach 8.4 mg / g.d without depending on plant growth hormone (which is a rigid biological index).

This invention provides single-domain antibodies or antigen-binding fragments thereof that specifically bind to growth hormone (e.g., human growth hormone), polypeptide constructs and conjugates containing said single-domain antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding said single-domain antibodies or antigen-binding fragments thereof, and host cells containing them, as well as related uses. Furthermore, it provides uses of said single-domain antibodies or antigen-binding fragments thereof, polypeptide constructs, or conjugates for the purification and / or detection of growth hormone (e.g., human growth hormone).

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral growth hormone pharmaceutical composition and a preparation method thereof. The composition comprises at least one growth hormone with an effective dose, at least one absorption enhancer, at least one pH regulator and at least one excipient. The pharmaceutical composition disclosed by the invention effectively promotes the absorption of the oral growth hormone drug, and further improves the bioavailability of the growth hormone drug.

The invention relates to two variable spliceosomes of a cynoglossus semilaevis adcyap1b gene and application of the two variable spliceosomes, and belongs to the technical field of functional gene screening and application in the aquatic biotechnology, the two variable spliceosomes are adcyap1b-tv1 and adcyap1b-tv2, coding region CDS sequences of the adcyap1b-tv1 and the adcyap1b-tv2 are SEQ ID NO: 1 and SEQ ID NO: 2, and protein sequences of the adcyap1b-tv2 are SEQ ID NO: 3 and SEQ ID NO: 4. The two variable spliceosomes of the adcyap1b gene are applied to regulation and control of hormone secretion of the pituitary of the cynoglossus semilaevis. By adding the recombinant protein of which the two variable spliceosomes are adcyap1b-tv1 and adcyap1b-tv2 into pituitary cells, the expression of a growth hormone gene gh, a prolactin gene prl, a growth lactin gene sl, a proogonin gene pomc and an adrenocorticotropic hormone release hormone gene crh of the cynoglossus semilaevis is regulated and controlled, so that the growth and development of the cynoglossus semilaevis are influenced.

This invention discloses a gene ThERF053 related to lateral branch development in *Taxus chinensis*, its expressed protein, and its applications, belonging to the field of plant genetic engineering technology. This application cloned a *Taxus chinensis* ThERF053 gene, the nucleotide sequence of which is shown in SEQ ID NO:1, and the amino acid sequence of the expressed protein is shown in SEQ ID NO:2. By transferring the ThERF053 gene into the model plant *Populus*, transgenic poplars overexpressing ThERF053 showed a 980-5100-fold increase in ThERF053 expression, while the content of the growth hormone IAA in the transgenic poplar plants was lower than that in the control plants. After 30 days of growth, a significant increase in lateral branches was observed in the transgenic *Populus chinensis*. These experimental results indicate that ThERF053 is a key gene positively regulating lateral branch development in *Taxus chinensis*, and has important application value in the molecular breeding of *Taxus chinensis* and related tree species.

The present application relates to the technical field of biological medicine, in particular to a long-acting sustained-release human recombinant growth hormone fusion protein, a pharmaceutical composition and application thereof. The growth hormone fusion protein provided by the present application comprises a growth hormone and a temperature-sensitive elastin-like polypeptide. After subcutaneous injection of the fusion protein, phase transition occurs in situ at body temperature, and drug depots are formed. The drug is slowly released from the depots to the body circulation system, significantly prolonging the effective action time of a single injection of growth hormone, improving patient compliance, and improving pharmacokinetic parameters. The growth hormone fusion protein also has significantly improved biological stability and high biological activity, and has excellent application value and potential.

The invention relates to the field of polypeptides, in particular to a drug delivery system for targeting adipose tissues. The invention provides a targeted adipose tissue drug delivery system, which is characterized in that the drug delivery system comprises a growth hormone receptor targeted polypeptide, a nanoparticle carrier and a drug, the drug is loaded in the nanoparticle carrier, the polypeptide is connected with the nanoparticle carrier through an amido bond, and the polypeptide is connected with the nanoparticle carrier through an amido bond. The polypeptide is selected from the group consisting of SEQ ID NOs: 1 to 15. The drug delivery system provided by the invention can specifically and accurately deliver drugs (such as weight loss drugs and fluorescent dyes) to adipose cells, so as to target adipose tissues, so that the drugs can play a better role.

The invention belongs to the technical field of biological medicine and nano-drug delivery, and particularly relates to a long-acting growth hormone (hGH) wrapped bacterial outer membrane vesicle and application, and the outer membrane vesicle GH-OMVs wraps a human growth hormone mutant with an amino acid sequence shown as SEQ ID NO: 1. The GH-OMVs provided by the invention can be used for preparing medicines or preparations for preventing and / or treating diseases related to growth hormone deficiency or growth hormone-related metabolic disorder, including but not limited to growth hormone deficiency, dwarf / low height, osteoporosis and the like, and has a good clinical application prospect.

The present disclosure relates, in general, to methods of treating short stature disorders in a subject who is non-responsive to growth hormone therapy using variants of C-type natriuretic peptide (CNP).

The present application relates to a kind of Fc mutant, fusion protein, nucleic acid molecule, expression vector, recombinant cell, pharmaceutical composition and its purposes.Fc mutant has the amino acid sequence as any one of SEQ ID NO:3~7;Fusion protein includes: second peptide segment, second peptide segment is the functional region of bioactive molecule, third peptide segment, third peptide segment includes the amino acid sequence shown in SEQ ID NO:2 or the Fc mutant of preceding, second peptide segment is connected with third peptide segment.The Fc mutant of the present application is monomer form, fusion protein has higher in vitro and in vivo activity and lower ADCC, CDC effect, can effectively treat growth hormone deficiency.